Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
By: Ross Blau
Life Sciences IP Review
Axinn associate Ross Blau co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
Shifting Trends in Healthcare Antitrust Enforcement: Navigating the Evolving Landscape
Axinn Viewpoints
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
In Fashion, One Day You’re In and the Next Day You’re Out (Of Chances to Plead Violations of the Sherman Act)
Axinn Viewpoints
Antitrust